97A8E2B1-059B-4527-8FB4-116F718FFD16
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.83837056504599
- age_years
- 58
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.563
- MYC_TARGETS_V1+0.541
- INTERFERON_ALPHA_RESPONSE+0.538
- ALLOGRAFT_REJECTION+0.509
- IL6_JAK_STAT3_SIGNALING+0.505
- OXIDATIVE_PHOSPHORYLATION+0.499
- INFLAMMATORY_RESPONSE+0.478
- TNFA_SIGNALING_VIA_NFKB+0.474
- E2F_TARGETS+0.434
- MTORC1_SIGNALING+0.433
Top 10 suppressed
- KRAS_SIGNALING_DN-0.351
- HEDGEHOG_SIGNALING-0.325
- WNT_BETA_CATENIN_SIGNALING-0.323
- MITOTIC_SPINDLE-0.307
- MYOGENESIS-0.278
- APICAL_SURFACE-0.269
- APICAL_JUNCTION-0.188
- ESTROGEN_RESPONSE_EARLY-0.148
- SPERMATOGENESIS-0.136
- PANCREAS_BETA_CELLS-0.092
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.982 |
| 2 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.981 |
| 3 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.980 |
| 4 | E89DB941-19C3-4CD9-9117-EAAF3B2AFD76 | — | — | 0.979 |
| 5 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.971 |
| 6 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.968 |
| 7 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.966 |
| 8 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.961 |
| 9 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.960 |
| 10 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.563 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.541 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.538 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.509 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.505 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.499 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.478 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.474 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.434 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.433 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.431 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.412 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.391 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.389 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.385 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.381 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.358 | Inavolisib | — uncovered |
| COAGULATION | 0.349 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.335 | Inavolisib | — uncovered |